share_log

CRISPR Therapeutics | 3: Initial statement of beneficial ownership of securities-Officer Bruno Julianne

CRISPR Therapeutics | 3: Initial statement of beneficial ownership of securities-Officer Bruno Julianne

CRISPR Therapeutics | 3:首次持股聲明-高管 Bruno Julianne
美股sec公告 ·  05/23 16:32
Moomoo AI 已提取核心訊息
Julianne Bruno, Chief Operating Officer of CRISPR Therapeutics, filed an Initial Statement of Beneficial Ownership of Securities with the SEC on May 23, 2024. The filing, required under Section 16(a) of the Securities Exchange Act of 1934, details Bruno's direct and indirect ownership of CRISPR Therapeutics' common shares and derivative securities, including stock options and restricted stock units (RSUs). Bruno directly owns 3,111 common shares and indirectly owns 7,088 shares through the Julianne Bruno 2022 GRAT. The filing also lists multiple stock options with varying exercise prices and expiration dates, ranging from May 1, 2029, to March 20, 2034, and RSUs with vesting schedules extending to March 20, 2028. The document outlines the vesting conditions of these securities, indicating a structured plan for share ownership over the coming years.
Julianne Bruno, Chief Operating Officer of CRISPR Therapeutics, filed an Initial Statement of Beneficial Ownership of Securities with the SEC on May 23, 2024. The filing, required under Section 16(a) of the Securities Exchange Act of 1934, details Bruno's direct and indirect ownership of CRISPR Therapeutics' common shares and derivative securities, including stock options and restricted stock units (RSUs). Bruno directly owns 3,111 common shares and indirectly owns 7,088 shares through the Julianne Bruno 2022 GRAT. The filing also lists multiple stock options with varying exercise prices and expiration dates, ranging from May 1, 2029, to March 20, 2034, and RSUs with vesting schedules extending to March 20, 2028. The document outlines the vesting conditions of these securities, indicating a structured plan for share ownership over the coming years.
CRISPR Therapeutics首席運營官朱麗安·布魯諾於2024年5月23日向美國證券交易委員會提交了初步的證券實益所有權聲明。根據1934年《證券交易法》第16(a)條的要求,該文件詳細說明了布魯諾對CRISPR Therapeutics普通股和衍生證券(包括股票期權和限制性股票單位(RSU)的直接和間接所有權。布魯諾直接擁有3,111股普通股,並通過朱麗安·布魯諾2022年GRAT間接擁有7,088股股票。該文件還列出了行使價和到期日各不相同的多個股票期權,範圍從2029年5月1日到2034年3月20日不等,以及歸屬時間表延至2028年3月20日的限制性股票單位。該文件概述了這些證券的歸屬條件,指出了未來幾年的結構化股份所有權計劃。
CRISPR Therapeutics首席運營官朱麗安·布魯諾於2024年5月23日向美國證券交易委員會提交了初步的證券實益所有權聲明。根據1934年《證券交易法》第16(a)條的要求,該文件詳細說明了布魯諾對CRISPR Therapeutics普通股和衍生證券(包括股票期權和限制性股票單位(RSU)的直接和間接所有權。布魯諾直接擁有3,111股普通股,並通過朱麗安·布魯諾2022年GRAT間接擁有7,088股股票。該文件還列出了行使價和到期日各不相同的多個股票期權,範圍從2029年5月1日到2034年3月20日不等,以及歸屬時間表延至2028年3月20日的限制性股票單位。該文件概述了這些證券的歸屬條件,指出了未來幾年的結構化股份所有權計劃。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息